Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Lin, Tsung Li ^a   Wang, Shyu Jye ^a   Fong, Yi Chin ^a   Hsu, Chin Jung ^a   Hsu, Horng Chaung ^a   Tsai, Chun Hao ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Alendronate; Atypical femoral fracture; Bone forming agents; Union

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BONE NAIL; FEMALE; FEMUR FRACTURE; HUMAN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE NAILS; FEMALE; FEMORAL FRACTURES; HUMANS;

MLCS; MLOWN;

EID: 84872134542     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-11     Document Type: Article

References (21)

1. Severely suppressed bone turnover: a potential complication of alendronate therapy. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY, J Clin Endocrinol Metab 2005 90 3 1294 1301 15598694 (Pubitemid 40463979)
2. Severely suppressed bone turnover and atypical skeletal fragility. Visekruna M, Wilson D, McKiernan FE, J Clin Endocrinol Metab 2008 93 8 2948 2952 10.1210/jc.2007-2803 18522980
3. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F, J Clin Endocrinol Metab 2011 96 9 2675 2680 10.1210/jc.2011-0593 21752890
4. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. Dobnig H, Stepan JJ, Burr DB, Li J, Michalska D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I, J Bone Miner Res 2009 24 12 1998 2006 10.1359/jbmr.090527 19453263
5. Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Jobke B, Pfeifer M, Minne HW, Connect Tissue Res 2009 50 1 46 54 10.1080/03008200802412462 19212852
6. Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rizzoli R, Laroche M, Krieg MA, Frieling I, Thomas T, Delmas P, Felsenberg D, Rheumatol Int 2010 30 10 1341 1348 10.1007/s00296-010-1542-y 20512336
7. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E, Bone 2012 52 1 360 365 23072919
8. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the american society for bone and mineral research. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, J Bone Miner Res 2010 25 11 2267 2294 10.1002/jbmr.253 20842676
9. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ, J Trauma 2011 71 1 186 190 10.1097/TA.0b013e31821957e3 21610533
10. Bisphosphonate use and atypical fractures of the femoral shaft. Schilcher J, Michaelsson K, Aspenberg P, N Eng J Med 2011 364 18 1728 1737 10.1056/NEJMoa1010650
11. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Recker RR, Marin F, Ish-Shalom S, Moricke R, Hawkins F, Kapetanos G, de la Pena MP, Kekow J, Farrerons J, Sanz B, J Bone Miner Res 2009 24 8 1358 1368 10.1359/jbmr.090315 19338452
12. A rational approach to management of alendronate-related subtrochanteric fractures. De Das S, Setiobudi T, Shen L, J Bone Joint Surg Br 2010 92 5 679 686 10.1302/0301-620X.92B5.22941 20436006
13. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS, J Bone Joint Surg Br 2007 89 3 349 353 10.1302/0301-620X.89B3.18146 17356148 (Pubitemid 46563912)
14. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, Garcia-Hernandez PA, Recknor CP, Einhorn TA, Dalsky GP, J Bone Miner Res 2010 25 2 404 414 10.1359/jbmr.090731 19594305
15. Effect of strontium ranelate on fracture healing in the osteoporotic rats. Ozturan KE, Demir B, Yucel I, Cakici H, Yilmaz F, Haberal A, J Orthop Res 2011 29 1 138 142 10.1002/jor.21204 20726035
16. Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Li YF, Luo E, Feng G, Zhu SS, Li JH, Hu J, Osteoporos Int 2010 21 11 1889 1897 10.1007/s00198-009-1140-6 19957162
17. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. Peichl P, Holzer LA, Maier R, Holzer G, J Bone Joint Surg Am 2011 93 17 1583 1587 10.2106/JBJS.J.01379 21915572
18. Parathyroid hormone and bone healing. Ellegaard M, Jorgensen NR, Schwarz P, Calcif Tissue Int 2010 87 1 1 13 10.1007/s00223-010-9360-5 20428858
19. Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates. Sousa IO, Diniz ET, Marques TF, Griz L, Coutinho Mde A, Bandeira F, Arq Bras Endocrinol Metabol 2010 54 2 244 249 10.1590/S0004-27302010000200023 20485916
20. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. Capeci CM, Tejwani NC, J Bone Joint Surg Am 2009 91 11 2556 2561 10.2106/JBJS.H.01774 19884427
21. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C, Bone 2003 33 3 301 307 10.1016/S8756-3282(03)00112-1 13678770 (Pubitemid 37103246)